◆英語タイトル：Symphogen AS - Strategic SWOT Analysis Review
◆商品コード：DATA8012830
◆発行会社（調査会社）：
GlobalData
◆発行日：2017年11月29日
◆ページ数：26
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：デンマーク
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
Symphogen AS – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights
Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics to enhance the lives of patients with cancer and other diseases with significant unmet medical needs. Its product pipeline provides novel approaches to a wide range of cancer types including metastatic colorectal cancer (mCRC), glioblastoma (GBM), solid tumor malignancies and MET-amplified solid tumors and partner targets. It has collaborations for the development of antibody therapeutics in immuno-oncology with Shire and infectious disease area with Genentech. Symphogen has offices in Denmark and New Jersey, the US.
Symphogen AS Key Recent Developments
Sep 14,2016: Symphogen Names New Chief Financial Officer
Aug 18,2016: Symphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director
May 11,2016: Symphogen Announces the Appointment of Jeffrey H. Buchalter and Christoffer Soderberg as Non-Executive Directors
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
Symphogen A/S – Key Facts 5
Symphogen A/S – Key Employees 6
Symphogen A/S – Key Employee Biographies 7
Symphogen A/S – Major Products and Services 8
Symphogen A/S – History 9
Symphogen A/S – Company Statement 11
Symphogen A/S – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Symphogen A/S – Business Description 13
Symphogen A/S – Corporate Strategy 14
Symphogen A/S – SWOT Analysis 15
SWOT Analysis – Overview 15
Symphogen A/S – Strengths 15
Symphogen A/S – Weaknesses 16
Symphogen A/S – Opportunities 17
Symphogen A/S – Threats 18
Symphogen A/S – Key Competitors 19
Section 3 – Company’s Lifesciences Financial Deals and Alliances 20
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 20
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 21
Symphogen A/S, Recent Deals Summary 22
Section 4 – Company’s Recent Developments 23
Sep 14, 2016: Symphogen Names New Chief Financial Officer 23
Aug 18, 2016: Symphogen’s Founding CEO Kirsten Drejer Steps Down and Becomes Executive Director 24
May 11, 2016: Symphogen Announces the Appointment of Jeffrey H. Buchalter and Christoffer Soderberg as Non-Executive Directors 25
Section 5 – Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Tables
Symphogen A/S, Key Facts 5
Symphogen A/S, Key Employees 6
Symphogen A/S, Key Employee Biographies 7
Symphogen A/S, Major Products and Services 8
Symphogen A/S, History 9
Symphogen A/S, Subsidiaries 12
Symphogen A/S, Key Competitors 19
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 20
Symphogen A/S, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 21
Symphogen A/S, Recent Deals Summary 22
